Skip to main content

Day: September 10, 2020

レッドヒル・バイオファーマのオパガニブ、SARS-CoV-2を完全に阻害

ヒト気管組織のin vitroモデルで3日間培養後、オパガニブがSARS-CoV-2ウイルス複製を完全に阻害し、陽性対照のレムデシビルよりも良好な試験結果を示した— オパガニブはCOVID-19治療に可能性が見込まれる経口投与薬で、強力な抗ウイルスおよび抗炎症作用機序を併せ持ち、宿主細胞を標的として、抵抗性を最低限に抑える—COVID-19による重症肺炎患者を対象にオパガニブの国際治験第2/第3相と米国での第2相試験を実施中— レッドヒルのCOVID-19薬第2候補であるRHB-107 (ウパモスタット) は、新奇のセリンプロテアーゼ阻害剤で、同じモデルでSARS-CoV-2ウイルス複製の強力な阻害作用が認められ、今年後半に米国の外来患者を対象に第2/第3相試験開始に向けて、さらに裏付けが得られたイスラエル・テルアビブおよびノースカロライナ州ローリー発, Sept. 11, 2020 (GLOBE NEWSWIRE) — 特殊製薬会社のレッドヒル・バイオファーマ (RedHill Biopharma Ltd.) (Nasdaq: RDHL) (以下「レッドヒル」または「同社」) は本日、オパガニブ (opaganib)1がCOVID-19の原因ウイルスであるSARS-CoV-2に対して強力な阻害作用を示し、ヒト肺気管組織のin vitroモデルでウイルス複製を完全に阻害したことを発表した。オパガニブはファーストインクラスの経口投与スフィンゴシンキナーゼ2 (SK2) 選択阻害剤で、宿主細胞成分を標的として抗炎症活性と抗ウイルス活性を示し、ウイルスの突然変異による影響を受けず、抵抗性を最低限に抑える。オパガニブは現在、COVID-19による重症肺炎患者治療を対象に、国際治験第2/第3相と米国での第2相試験が実施されている。オパガニブの試験は、ルイビル大学予防医学センターと協力して、ヒト気管上皮細胞 (EpiAirway™)...

Continue reading

Opaganib Keluaran RedHill Biopharma Menunjukkan Perencatan Penuh SARS-CoV-2

Selepas pengeraman selama tiga hari dalam model in vitro tisu bronkus manusia, ukuran menunjukkan opaganib telah merencatkan sepenuhnya pereplikaan virus SARS-CoV-2, setanding dengan remdesivir yang merupakan kawalan positif dalam kajian ini—Opaganib berada pada kedudukan yang unik sebagai rawatan dalam bentuk oral yang berpotensi untuk merawat COVID-19 dengan menggabungkan mekanisme tindakan antivirus dan antiradang yang berkesan, menyasarkan komponen sel hos dan mengurangkan kebarangkalian rintangan—Kajian klinikal Fasa 2/3 Global dan Fasa 2 A.S. terhadap opaganib sebagai rawatan pneumonia COVID-19 tahap teruk sedang dijalankan —Calon ubat COVID-19 RedHill yang kedua, RHB-107 (upamostat), sejenis perencat protease serina baharu telah berjaya merencatkan pereplikaan virus SARS-CoV-2 dalam model yang sama, sekali gus...

Continue reading

Opaganib ของ RedHill Biopharma สามารถยับยั้งเชื้อ SARS-CoV-2 ได้อย่างสมบูรณ์

Opaganib สามารถยับยั้งการจำลองตัวเองของเชื้อไวรัส SARS-CoV-2 ได้เมื่อทำการวัดผลหลังจากทำการเพาะเชื้อในโมเดลจำลองเนื้อเยื่อของมนุษย์ในหลอดทดลองไปแล้วเป็นเวลา 3 วันเมื่อเปรียบเทียบกับยาเรมดิสิเวียร์ (Remdesivir) ซึ่งเป็นตัวควบคุมบวกในการศึกษานี้ในทางที่ดี—สิ่งที่ทำให้ Opaganib โดดเด่นคือการเป็นยารูปแบบรับประทานทางปากที่อาจจะสามารถใช้รักษาโควิด-19 ได้ ด้วยกลไกการออกฤทธิ์ซึ่งรวมทั้งการกำจัดเชื้อไวรัสและการลดการอักเสบได้อย่างมีประสิทธิภาพ มุ่งเป้าไปที่ส่วนประกอบของเซลล์เจ้าบ้าน (Host Cell) และลดโอกาสในการดื้อยา—กำลังมีการศึกษาวิจัยทางคลินิกของ Opaganib ในระยะ 2/3 ทั่วโลก และระยะ 2 ในสหรัฐอเมริกาสำหรับใช้เพื่อรักษาภาวะปอดอักเสบอย่างรุนแรงจากการติดเชื้อโควิด-19—ยา RHB-107 (ยา Upamostat) ยาในลำดับที่สองของ RedHill ที่อาจสามารถใช้รักษาโควิด-19 ได้นั้นเป็นยาใหม่ในกลุ่มที่ทำการยับยั้งเอนไซม์ Serine Protease สามารถยับยั้งการจำลองเชื้อไวรัส...

Continue reading

PDC Energy Announces Pricing of $150 Million Tack-On Senior Notes Offering

DENVER, Sept. 10, 2020 (GLOBE NEWSWIRE) — PDC Energy, Inc. (“PDC” or the “Company”) (Nasdaq:PDCE) today announced that it has priced its previously announced public offering of an additional $150 million aggregate principal amount of its existing 5.75% Senior Notes due 2026 (the “Existing Notes”) at an issue price of 99.0% of face value, plus accrued and unpaid interest from May 15, 2020 to but excluding the settlement date for the notes.The Notes will be treated as a single series with the Existing Notes under the indenture governing the Existing Notes and will have the same terms as the Existing Notes (other than the initial offering price and the issue date).  The Notes will have the same CUSIP number and will trade interchangeably with the Existing Notes. The Company expects the Notes and the Existing...

Continue reading

Fred Kao Named Vice President of Global Sales for Amlan International

CHICAGO, Sept. 10, 2020 (GLOBE NEWSWIRE) — Amlan International, a global leader in developing innovative solutions that improve livestock intestinal health and productivity, is proud to name Fred H. Kao for the new role of Vice President of Global Sales.The creation of this position further supports the company’s investment in the gut health product line for the global market. Driven by increasing consumer demand for protein produced without antibiotics, Amlan International is excited to move confidently forward to provide animal health solutions for their customers.Kao brings to the company 20 years of expertise in building strong relationships with key integrators in the animal protein business. Kao has worked in Europe, Middle East, African and Asia Pacific regions since 2004. He most recently managed the Asia Pacific business...

Continue reading

Inscape Announces First Quarter Financial Results

HOLLAND LANDING, Ontario, Sept. 10, 2020 (GLOBE NEWSWIRE) — Inscape (TSX: INQ), a leading designer and manufacturer of furnishings for the workplace, today announced its results of operations for the first quarter ended July 31, 2020. “First Quarter Fiscal Year 2021 results are encouraging given the challenges the Company is facing during the COVID-19 pandemic,” said Eric Ehgoetz, CEO.  “While sales declines were anticipated, management has continued to aggressively manage working capital and maintain cash levels consistent with the prior quarter in order to allow the Company the necessary flexibility to execute the actions required to adapt to the current environment.   While the Company continues to see weakness in its Systems and Storage divisions, we note a strengthening of demand in the Walls division, which is not unexpected...

Continue reading

The Becker Milk Company Limited: Three Month Financial Results and Regular Dividend

TORONTO, Sept. 10, 2020 (GLOBE NEWSWIRE) — The Becker Milk Company Limited (the “Company”) (TSX-BEK.B) is pleased to report the results for the three months ended July 31, 2020.HIGHLIGHTSTotal revenues for the three months ended July 31, 2020 were $768,472 compared to $797,868 for the same period in 2019;Net operating income for Q1 fiscal 2021 was $639,922 compared to $671,539 in fiscal 2020;Net income for Q1 fiscal 2021 was $0.15 per share, compared to $0.13 per share in fiscal 2020.FINANCIAL HIGHLIGHTSNet operating income for the three months ended July 31, 2020 was $639,922, a $31,617 decrease compared with the previous year as a result of decreased revenue for the quarter.Components of the $34,661 increase in net income for the three months ended July 31, 2020 compared to the three months ended July 31, 2019 are:ADJUSTED FUNDS...

Continue reading

ACME AtronOmatic, LLC, Creators of MyRadar App, Acquires EndpointAI

ORLANDO, Fla., Sept. 10, 2020 (GLOBE NEWSWIRE) — ACME AtronOmatic, LLC, the makers of the popular MyRadar weather app, announced today that it has acquired EndpointAI Inc., a weather technologies company, specializing in enhanced forecasting for surface transportation.Endpoint, the brainchild of two applied meteorology experts hailing from the National Center for Atmospheric Research, showcases unique, machine-learning enhanced road condition and road risk forecasts with cutting-edge ground-truth validation.ACME will leverage the technology and capabilities from Endpoint and integrate road condition forecasts into the MyRadar app for both consumer and commercial use, allowing users to obtain route-based weather for long-haul travel.  Endpoint’s algorithms will be further enhanced by integration with MyRadar’s patent-pending,...

Continue reading

SteraMist Continues to Provide Proven, Regulated Disinfection for COVID-19 and Other Pathogens

BEVERLY HILLS, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (OTCQB:TOMZ), is a global company specializing in disinfection and decontamination, utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist products – a hydrogen peroxide-based mist and fog composed of ionized Hydrogen Peroxide (iHP).Coronavirus and COVID-19 has brought disinfection into the global spotlight. The SteraMist brand of products continues to provide all-encompassing disinfection globally to combat coronavirus as well as the highest resistant pathogens known to mankind.TOMI has been at the forefront of disinfection and focused on establishing SteraMist as the standard for enhanced disinfection throughout multiple sectors through its widespread application before COVID-19 with the...

Continue reading

Home BancShares, Inc. To Host Fireside Chat on Office Segment

CONWAY, Ark., Sept. 10, 2020 (GLOBE NEWSWIRE) — Home BancShares, Inc. (NASDAQ GS: HOMB), parent company of Centennial Bank, announced that they will host another Fireside chat featuring their Office segment. The call will be held Tuesday, September 15, 2020 at 1:00pm CT (2:00pm ET). The management team of HOMB will host the call.To join the call, participants can dial 1-877-508-9586 or join the live webcast at https://services.choruscall.com/links/homb200915.html. Pre-registration for the call is not required. A presentation will be available on the company website, www.homebancshares.com, at the start of the conference call.“Our Fireside Chat series has proven to be a successful dialogue platform during these socially distant and uncertain times,” stated John Allison, Chairman. “We have received positive feedback on the transparency...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.